FAQ on HeartBeam Inc.'s Expansion of Cardiac Monitoring IP Portfolio with New U.S. Patents

What are the two new U.S. patents issued to HeartBeam Inc.?

The first patent covers HeartBeam’s credit card-sized, cable-free 3D ECG device for real-time cardiac monitoring, and the second protects its rhythm analysis algorithm that detects arrhythmias and prompts ECG data collection.

How many patents does HeartBeam Inc. now hold?

HeartBeam Inc. now holds 20 issued patents and has 34 others pending or allowed, including 13 U.S. and 4 international-issued patents related to its technology.

What is the significance of these patents for HeartBeam Inc.?

These patents bolster HeartBeam’s intellectual property portfolio, reinforcing its platform ahead of future product extensions and FDA review of its 12-lead ECG synthesis software.

What technology does HeartBeam Inc. specialize in?

HeartBeam specializes in creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions, designed for portable use outside medical facilities.

Where can I find more information about HeartBeam Inc.?

More information about HeartBeam Inc. can be found on their website at www.HeartBeam.com and in their newsroom at https://ibn.fm/BEAT.

What is the purpose of HeartBeam’s rhythm analysis algorithm?

The rhythm analysis algorithm identifies arrhythmias using continuous signal input and prompts users to collect 3D ECG data when anomalies are detected, enhancing cardiac monitoring and care.

How does HeartBeam’s technology transform cardiac care?

HeartBeam’s technology enables portable, cable-free ECG monitoring outside medical facilities, allowing physicians to identify cardiac health trends and acute conditions, thus redefining cardiac health management.

What future developments can be expected from HeartBeam Inc.?

HeartBeam is preparing for future product extensions and the FDA review of its 12-lead ECG synthesis software, indicating ongoing innovation in personalized cardiac care.